Geron Deferred Long Term Liab from 2010 to 2024

GERN Stock  USD 4.17  0.11  2.71%   
Geron Deferred Long Term Liabilities yearly trend continues to be very stable with very little volatility. Deferred Long Term Liabilities is likely to drop to 0.00. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2011-06-30
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
9.1 K
 
Yuan Drop
 
Covid
Check Geron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Geron's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 8.7 M or Selling General Administrative of 72.6 M, as well as many indicators such as Price To Sales Ratio of 5.3 K, Dividend Yield of 0.0 or PTB Ratio of 2.86. Geron financial statements analysis is a perfect complement when working with Geron Valuation or Volatility modules.
  
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock:
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.33)
Revenue Per Share
0.047
Quarterly Revenue Growth
171.384
Return On Assets
(0.30)
Return On Equity
(0.69)
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.